新辅助化疗在宫颈癌治疗中的应用  

Neoadjuvant Chemotherapy in Cervical Cancer

作　　者：陈雪梅[1] 

机构地区：[1]广东省怀集县人民医院,广东肇庆526400

出　　处：《临床医学工程》2012年第12期2184-2185,共2页Clinical Medicine & Engineering

摘　　要：目的观察新辅助化疗治宫颈癌临床效果和安全性。方法 126例宫颈癌患者应用随机数字表法分为A组和B组,A组患者给予手术和术后放化疗等综合治疗,而B组患者则在术前先给予新辅助化疗,比较两组患者临床疗效和药物不良反应发生情况。结果 B组患者的治疗总有效率(80.95%)明显高于A组患者的(63.49%),差异有统计学意义(P<0.05),而A组和B组不良反应发生率差异无统计学意义(P>0.05)。结论新辅助化疗治宫颈癌疗效确切,具有安全高效和不良反应少等特点。Objective To observe the clinical effect and safety of the neoadjuvant chemotherapy for cervical cancer. Methods From February 2008 to February 2012 in our hospital for treatment of 126 cases with cervical carcinoma as the research object, using a random number table would be consistent with this study inclusion criteria and exclusion criteria were divided into A group and B group, A group were treated with operation and postoperative chemotherapy comprehensive treatment, B group patients in preoperative to neoadjuvant chemotherapy, compared with A group and B group of patients with clinical efficacy and adverse drug reaction. Results The patients in the B group total effective rate （80.95%） was significantly higher than that of A group （63.49%）, the difference was statistically significant （P〈0.05）, A group and B group, the incidence of adverse reactions were not statistically significant （P 〉0.05）. Conclusions The curative effect of neoadjuvant chemotherapy for cervical cancer, is safe and efficient and less adverse reaction characteristics.

关 键 词：新辅助化疗 宫颈癌 临床疗效 

分 类 号：R737.33[医药卫生—肿瘤]